MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF)

A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2041250057

Enrollment

Registered

2025-07-08

Start date

2025-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure with Preserved Ejection Fraction

Interventions

Double-Blind, Placebo-Controlled, Study Arms:BMS-986435 and Placebo Comparator group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.

Exclusion criteria

Exclusion criteria: - Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant. - Other protocol-defined Inclusion/Exclusion criteria apply.

Design outcomes

Primary

Measure	Time frame
- Incidence of treatment emergent adverse events (TEAEs) - Incidence of serious adverse events (SAEs) - Incidence of AEs leading to treatment discontinuation	—

Secondary

Measure	Time frame
Summary of plasma concentrations of MYK-224	—

Countries

Argentina, Canada, China, Israel, Japan, Korea, United Kingdom, United States

Contacts

Public ContactMarzia Rigolli

Bristol-Myers Squibb

MG-JP-RCO-JRCT@bms.com+81-120-093-507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026